Phase I
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
Adastra Pharmaceuticals’ positive results from a Phase Ib trial of its therapy for recurrent high-grade glioblastomas suggest an effective treatment could be available within the next several years.
The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.
PRESS RELEASES